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How does the skin resist infection by organisms that im-
pinge or reside on its surface? In this issue, Lo´pez-Garcı´a
et al (2005) report on one aspect of this larger question, by
describing experiments on the potential role of cathelicidins
in protecting the skin from Candida albicans. My commen-
tary begins with a historical perspective and ends with
some caveat lector statements.
Historical Perspective
Over a century ago, Eli Metchnikoff wrote: ‘‘The pyogenic
cocci, staphylococci, and streptococci, are constantly
found on human skin, most frequently hidden in the depths
of the canals of hair follicles. These micro-organisms seize
every opportunity to attack the organism, producing such
local lesions as acne, pimples, boils, and erisipelas [SIC] or
even becoming generalized in the blood and tissues as in
the septicemias and pyemias. To the skin, therefore, must
be assigned a very important function in the prevention of
the invasion of micro-organisms, which are found constant-
ly on the surface of the body. . .’’ (Metchnikoff, 1905).
Early investigators of cutaneous defenses gave primacy
to the mechanical properties of the skin, and especially to
the cleansing effects of shedding superficial keratinocytes
with their cargo of attached bacteria. More recent studies
have, however, shown that cutaneous defenses also have a
chemical basis. Keratinocytes and skin appendages pro-
duce a host of antimicrobial proteins and peptides. In hu-
mans, these include b-defensins, LL-37, dermcidin (DCD),
psoriasin (S100A7), and adrenomedullin (AM). Their inter-
play begins even before birth, since many of these mole-
cules are present in the lipid-rich film (vernix caseosa) that
adheres to fetal and neonatal skin (Marchini et al, 2002).
Antimicrobial Peptides of Skin
LL-37, the subject of the Lo´pez-Garcı´a report, is only one of
the peptides that acts in defense of skin. As described be-
low, many of the others also have activity against C. albi-
cans. This redundancy contributed to the lack of any
enhanced susceptibility for C. albicans in the mCRAMP
knockout mice. Of course, there are advantages to having a
multicomponent defense system. It decreases the likelihood
that resistant organisms will emerge, and it increases the
possibility of having additive or synergistic effects.
Human LL-37 and its murine homologue mCRAMP are
classified as cathelicidins, because their precursors contain
a conserved  100 amino acid C-terminal domain called
‘‘cathelin’’ (Lehrer and Ganz, 2002). hCAP-18, the cathelin-
containing precursor of LL-37, is induced in normal kera-
tinocytes by injury and inflammation. hCAP is also a major
component of the secondary (specific) granules of human
neutrophils, and is also found in human semen. LL-37
shows activity against C. albicans in vitro, even in physio-
logical saline solutions. This is important because the skin
surface is quite salty, because of the delivery and subse-
quent evaporation of sweat.
Genes for at least 30 different human b-defensins (HBD)
exist, but only three of them (HBD-1–3) have been widely
studied. All three are expressed by keratinocytes. The HBD
are small (4.5–5 kDa) cationic antimicrobial peptides with
six conserved cysteine residues and three intramolecular
disulfide bonds (Lehrer, 2004). HBD-1 is produced con-
stitutively by keratinocytes, and its broad antimicrobial
spectrum includes Gram-negative bacteria and C. albicans.
HBD-2 is not expressed by normal skin, but is highly ex-
pressed by keratinocytes in psoriasis and in inflammatory
skin conditions. HBD-2 is cytoplasmic in the upper spinous
and granular layers of psoriatic skin, and extracellular in the
horny layer, where it occupies and permeates the intercel-
lular spaces (Huh et al, 2002). Keratinocytes produce HBD-
3 only in response to infectious or inflammatory stimuli. The
defensin is very active against Gram-positive bacteria,
including Staphylococcus aureus, and also has activity
against C. albicans (Hoover et al, 2003). Unlike HBD-1 and
HBD-2, the antimicrobial activity of HBD-3 remains robust in
environments with high salinity.
DCD is a 47 amino acid peptide produced in eccrine
sweat glands. DCD and its smaller, proteolytically proc-
essed derivatives are delivered to the skin surface in sweat.
The DCD peptides have a broad antimicrobial spectrum,
which includes Escherichia coli, E. faecalis, S. aureus, and
C. albicans. Thus, the delivery of DCD by sweating may
regulate the density and composition of human skin flora
(Schittek et al, 2001).
AM, a multifunctional 52-residue peptide with antimicro-
bial properties, is expressed in the spinous, granular, and
cornified layers of the epidermis. It is also expressed in
sweat glands, sweat ducts, and sebaceous glands (Allaker
et al, 1999). Although AM is highly active against Propioni-
bacterium acnes and Micrococcus luteus, it is inactive
against C. albicans (Allaker et al, 1999).
Abbreviations: DCD, dermcidin; HBD, human b-defensins; MRP,
myeloid-related protein
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Psoriasin (S100A7) is a small, secreted, calcium-binding
S100 protein that is highly active against E. coli. It is over-
expressed in psoriatic lesions, inflammatory skin diseases,
and cancer tissues (Glaser et al, 2005). Certain other S100
proteins are also overexpressed in psoriasis, including
S100A8 and S100A9. The latter two proteins have many
properties and also many aliases. S100A8 has also been
called calgranulin A and myeloid-related protein (MRP)-8;
S100A9 has been called calgranulin B and MRP-14. MRP-8/
MRP-14 heterodimers have been called L1 protein, cystic
fibrosis antigen, and calprotectin. The MRP-8/MRP-14 he-
terodimer not only constitutes over half of the total cyto-
plasmic protein of the human neutrophil, it also has
prominent antimicrobial properties. In vitro, 4–32 mg per
mL of the heterodimer inhibits growth of C. albicans, and
higher concentrations inhibit the growth of Gram-positive
and Gram-negative bacteria (Brandtzaeg et al, 1995).
Although S100A8 and S100A9 are absent or expressed
at minimal levels in normal epidermis, both are greatly
overexpressed in the basal and spinous layers in psoriasis
(Broome et al, 2003). The antimicrobial activity of psoriasin
(S100A7) and of calprotectin (S100A8/S100A9) is inhibited
by zinc. Some investigators interpret this to mean that S100
proteins exert their activity against C. albicans by depriving
the target organism of zinc. Others (e.g., the author of this
commentary) consider this unproven for reasons that were
reported elsewhere (Murthy et al, 1993).
C. albicans
This yeast-like organism commonly exists in relatively low
numbers on the mucosal surfaces of the human mouth,
vagina, and intestinal tract. It has few nutritional require-
ments, needing only an exogenous source of biotin to pro-
liferate on simple glucose-salts media. C. albicans dwelling
on a mucous membrane must compete with a much larger
biomass of bacteria for ambient biotin. Both oral strepto-
cocci and vaginal lactobacilli also require biotin. Conse-
quently, C. albicans gains a competitive advantage when
administration of broad-spectrum antibiotics reduces the
density of surrounding biotin-dependent microbes. Cutane-
ous candidiasis most often occurs in skin areas that remain
moist, e.g., under diapers or in the perianal area.
Candida skin infections almost never lead to systemic
infection in the absence of other predisposing factors, such
as severe neutropenia, leukemia, indwelling lines, etc. This
is largely attributable to factors that are more than skin
deep—i.e., the vast army of neutrophils, monocytes, ma-
crophages, and NK cells that individually and collectively
are active against this organism.
Caveats
I wrote this commentary aware that the world will little note
or long remember what is said here. Nevertheless, I will
share three comments that are related to the article by
Lo´pez-Garcı´a et al.
The first comment is technical. In my 30 years of working
with antimicrobial peptides, I have observed several that
bind so avidly to cellulose acetate that they are difficult to
elute. Thus, sweat should be collected directly in any future
studies, rather than onto KimWipes or other forms of cel-
lulose acetate.
The second comment is philosophical. Systemic resist-
ance to C. albicans should not be equated with the results
of a ‘‘blood killing assay’’. Systemic resistance to any or-
ganism is the resultant, over time, of many different cell
types, processes, and molecules. It is highly unlikely that
all of these were represented in the assay tubes that, for
3 hours, contained mouse blood and C. albicans.
The third comment is related to experimental design.
Why would one use a subcutaneous route of C. albicans
inoculation to test the defense mechanisms of skin keratin-
ocytes? Would this route not place the organisms beyond
the reach of keratinocytes and into the realm where sys-
temic defenses predominate?
Any readers who might wish to enlighten, chastise, or
challenge me on any of the above comments, can do so by
e-mail at rlehrer@mednet.ucla.edu.
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